To evaluate the cost-effectiveness of dalbavancin compared with standard of care (SoC) treatment as daptomycin or teicoplanin in patients with sternal wound infections (SWI).
Pascale, R., Maccaro, A., Mikus, E., Baldassarre, M., Tazza, B., Esposito, F., et al. (2022). A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 30, 390-394 [10.1016/j.jgar.2022.07.018].
A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study
Pascale, Renato;Maccaro, Angelo;Mikus, Elisa;Baldassarre, Maurizio;Tazza, Beatrice;Rinaldi, MatteoMembro del Collaboration Group
;Tenti, Elena;Ambretti, Simone;Viale, Pierluigi;Giannella, Maddalena;Bartoletti, Michele
2022
Abstract
To evaluate the cost-effectiveness of dalbavancin compared with standard of care (SoC) treatment as daptomycin or teicoplanin in patients with sternal wound infections (SWI).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pascale SWIT.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
545.03 kB
Formato
Adobe PDF
|
545.03 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
